All News

On social media, CURE® recently asked its readers to share the most surprising thing that’s changed in their life since receiving a cancer diagnosis. Here, we share some of their responses.

The day cancer treatment ends, a new chapter begins. Some survivors may leave cancer behind and continue life with few or no health problems. Others might have ongoing physical challenges. Some of these might be due to late effects (also called aftereffects) of cancer treatment.

A roundup of the latest news and updates for patients with metastatic breast cancer from CURE®.

The relationship that develops between a cancer patient and their oncology team is a most intimate thing.

Like the novel coronavirus, cancer is invisible, unrelenting, and always surrounding us.

Throughout the summer, CURE® highlighted many simple and healthy recipes that the oncology dietitians from the John Theurer Cancer Center put together for cancer survivors and patients. Here, we share some of those recipes.

A pancreatic cancer survivor offers other patients tips he has learned along his journey to help them get through their treatments.

A roundup of the latest news and updates for patients with prostate cancer from CURE®.

The Food and Drug Administration approves Gavreto for treatment of patients with metastatic, RET fusion-positive non-small cell lung cancer.

A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

Patients with cancer have a right to choose not to treat their illness, even if it’s not a popular decision.

From researchers identifying honeybee venom’s potential to kill cancer cells in a lab to a new study showing cancer risk was not significantly associated with use of permanent hair dye in women, here’s what’s happening in the cancer landscape this week.

The Food and Drug Administration granted a priority review to the new drug application for melflufen in combination with dexamethasone for adults with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy.

Allogeneic hematopoietic stem cell transplant’s role in the chronic lymphocytic leukemia has changed due to new novel agents, but research shows its still effective despite novel agent exposure.

Immediate treatment with Lynparza after standard surgery and chemotherapy should be considered for all patients with newly diagnosed stage 3 or 4 ovarian cancer that carries a BRCA gene mutation, even if residual disease remains, researchers have found.

It seems acceptable in our world to grieve the loss of a loved one, but unheard of to grieve the loss of body parts.

In our final recipe in the Cooking with CURE series, our oncology dietitian friends at the John Theurer Cancer Center provide an interesting twist on the classic hummus recipe.

Heightening the dose of the targeted drug Rituxan (rituximab) during the first four cycles of the R-CHOP regimen does not improve outcomes in treating patients with diffuse large B-cell lymphoma, the phase 3 HOVON-84 trial found.

An early phase 1b/2 study of Copiktra in combination of standard of care shows how the treatment is active for patients with chronic lymphocytic leukemia but further study is needed to ensure it is an effective and safe alternative to standard of care.

As the COVID-19 pandemic continues to impact the care of patients with metastatic renal cell carcinoma and other cancers, health care professionals are working together to stay vigilant and make the best treatment decisions for their patients by pooling their data with tools like the COVID-19 and Cancer Consortium, says Dr. Toni K. Choueiri.

“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an effective, safe, and ideally outpatient regimen for MCL,” the authors wrote.

The approval for patients with acute myeloid leukemia was based on data from the phase 3 QUAZAR AML-001 trial, which demonstrated that patients who received Onureg achieved a median overall survival of 24.7 months compared to 14.8 months for those who received placebo.

A two-time cancer survivor discusses how survivors sometimes get assigned an unwilling task of being a cancer educator or ambassador to friends and family.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for August 2020.

While the rare cancer landscape is growing, progress is happening thanks to patients advocating for their care.

On social media, CURE® recently asked its readers what their thoughts were on the medical use of cannabis. Here, we share some of their responses.